BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Denator AB Successfully Completes a 25.5 Million SEK Financing Round With Novo Seeds & Almi Invest as New Investors


3/26/2012 8:13:54 AM

Gothenburg, Sweden – Denator AB today announced that the company has successfully completed a sixth round of financing, raising 25.5 million SEK (2,75 MEuro). Major contributions came from new investors, Novo Seeds, the early stage investment group of Novo A/S, and the venture capital company, Almi Invest. Existing investors also participated in this round of financing.

In conjunction with the investment, Søren Møller, Managing Investment Director at Novo Seeds, will join the Board of Directors. Mr. Møller explained the background to the Novo Seeds decision: “We are very pleased to co-lead this round with Almi Invest. We believe that Denator’s innovative heat-stabilization technology offer significant value to protein researchers in important areas such as neurodegenerative diseases and cancer. This is Novo Seeds’ first device investment and confirms our continued interest in funding innovative science and entrepreneurship throughout Scandinavia.”

Olof Sköld, CEO at Denator, continued: "We are extremely happy to close this 25,5 million SEK investment and wish to thank our existing investors who have continuously shown their commitment. We also welcome Novo Seeds and Almi Invest to Denator. This funding is an important milestone in our commercial development, and will enable us to strengthen our product development to meet the need our customers and continue our market expansion. We will benefit greatly from the additional resources and experience from our new investors."

About Denator

Denator AB is a privately held biotech company based in Gothenburg, Sweden. Denator develops and markets products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. Based upon the company’s proprietary heat inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and so maintain the stability of sample components throughout the analytical workflow.

For more information, please contact:

Olof Sköld

CEO

Denator AB

E-mail: olof@denator.com

Tel.: +46 31 41 28 90

Fax.: +46 31 41 28 40


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->